Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Full story
Zai Lab announced that five of its commercial medicines are now part of China's 2026 National Reimbursement Drug List. This update includes first-time listings for KarXT and VYVGART Hytrulo. These inclusions are intended to expand patient access to these treatments within the country.
SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for […]